These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34107915)

  • 1. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
    BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G; Kumar S; Min KW; Silva FG
    Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Castleman's Disease during the Long-Term Course of Membranous Nephropathy.
    Nakajima S; Nagai K; Sakata A; Usui J; Yamagata K; Ueda A
    Case Rep Nephrol; 2023; 2023():4926000. PubMed ID: 36873956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
    Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
    BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid.
    Takeuchi N; Arai T; Kitaichi M; Inoue Y
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24072826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.
    Tosaki T; Okabe M; Suzuki T; Shimizu A; Koike K; Tsuboi N; Kawamura T; Ohashi R; Yano S; Yokoo T
    CEN Case Rep; 2021 May; 10(2):265-272. PubMed ID: 33389670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
    CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies.
    Ruggieri G; Barsotti P; Coppola G; Spinelli C; Balducci A; Ventola FR; d'Adamo G; Tata MV; Marinozzi V
    Am J Nephrol; 1990; 10(4):323-8. PubMed ID: 2240060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
    Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
    Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of multicentric Castleman's disease with membranoproliferative glomerulonephritis type 3-like lesion.
    Nagai K; Usui J; Noguchi K; Unai K; Hiwatashi A; Arakawa Y; Togashi A; Morito N; Saito C; Yoh K; Tsuruoka S; Kojima H; Aita K; Nagata M; Yamagata K
    Pathol Int; 2011 Nov; 61(11):686-90. PubMed ID: 22029682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.
    Maeshima A; Nakasatomi M; Henmi D; Yamashita S; Kaneko Y; Kuroiwa T; Hiromura K; Nojima Y
    CEN Case Rep; 2012 May; 1(1):7-11. PubMed ID: 28509146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schönlein purpura) responding well to tocilizumab: a case report.
    Oshima Y; Hoshino J; Suwabe T; Hayami N; Yamanouchi M; Sekine A; Ueno T; Mizuno H; Yabuuchi J; Imafuku A; Kawada M; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Hayashi N; Fujii T; Ubara Y
    Clin Rheumatol; 2017 Mar; 36(3):729-733. PubMed ID: 28168662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance of light chain isotypes between serum and glomerular deposits in proliferative glomerulonephritis with monoclonal IgG deposits: a case report and review of the literature.
    Miura S; Katayama K; Sugimoto Y; Tanaka F; Mori M; Takahashi D; Saiki R; Hirabayashi Y; Murata T; Tawara I; Dohi K
    BMC Nephrol; 2023 Jul; 24(1):199. PubMed ID: 37393252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
    Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
    Sugawara E; Sato T; Amasaki Y; Katsumata K
    Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease).
    Chan TM; Cheng IK; Wong KL; Chan KW
    Nephron; 1993; 65(4):628-32. PubMed ID: 8302422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A; Wada J; Morita Y; Baba M; Eguchi J; Nishimoto N; Okino T; Ichimura K; Yoshino T; Makino H
    Am J Kidney Dis; 2004 Jan; 43(1):E3-9. PubMed ID: 14712466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
    Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.